相似文献
1
Brain PET in the diagnosis of Alzheimer's disease.
Clin Nucl Med. 2014 Oct;39(10):e413-22; quiz e423-6. doi: 10.1097/RLU.0000000000000547.
2
Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Hong Kong Med J. 2016 Aug;22(4):327-33. doi: 10.12809/hkmj154707. Epub 2016 Jun 17.
3
Impact of molecular imaging on the diagnostic process in a memory clinic.
Alzheimers Dement. 2013 Jul;9(4):414-21. doi: 10.1016/j.jalz.2012.07.003. Epub 2012 Nov 16.
4
Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT.
Neuroradiol J. 2014 Feb;27(1):13-21. doi: 10.15274/NRJ-2014-10002. Epub 2014 Feb 24.
5
The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
J Neuroimaging. 2019 Nov;29(6):712-720. doi: 10.1111/jon.12643. Epub 2019 Jun 14.
6
Early differential diagnosis between Alzheimer's disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT.
Psychiatry Res Neuroimaging. 2016 Mar 30;249:105-12. doi: 10.1016/j.pscychresns.2015.12.007. Epub 2015 Dec 28.
7
Positron emission tomography imaging in dementia.
Br J Radiol. 2007 Dec;80 Spec No 2:S160-7. doi: 10.1259/bjr/97295129.
8
Clinical Relevance of [F]Florbetaben and [F]FDG PET/CT Imaging on the Management of Patients with Dementia.
Molecules. 2021 Feb 26;26(5):1282. doi: 10.3390/molecules26051282.
9
Molecular imaging of dementia.
Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x.
10
Evaluating 2-[F]FDG-PET in differential diagnosis of dementia using a data-driven decision model.
Neuroimage Clin. 2020;27:102267. doi: 10.1016/j.nicl.2020.102267. Epub 2020 Apr 24.
引用本文的文献
1
Identification of diffusion, kurtosis, and propagator MRI markers of Alzheimer's disease pathology in post-mortem human tissue.
Imaging Neurosci (Camb). 2024 May 8;2. doi: 10.1162/imag_a_00164. eCollection 2024.
2
Alzheimer's Disease Pathogenic Mechanisms: Linking Redox Homeostasis and Mitochondria-Associated Metabolic Pathways Through Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2).
Antioxidants (Basel). 2025 Jul 1;14(7):812. doi: 10.3390/antiox14070812.
3
Noise-aware system generative model (NASGM): positron emission tomography (PET) image simulation framework with observer validation studies.
Med Phys. 2025 Jul;52(7):e17962. doi: 10.1002/mp.17962.
4
Towards early diagnosis and screening of Alzheimer's disease using frequency locked whispering gallery mode microtoroids.
NPJ Biosens. 2024;1(1):9. doi: 10.1038/s44328-024-00009-8. Epub 2024 Aug 28.
5
Computational Risk Stratification of Preclinical Alzheimer's in Younger Adults.
Diagnostics (Basel). 2025 May 26;15(11):1327. doi: 10.3390/diagnostics15111327.
6
Evaluating EEG complexity and spectral signatures in Alzheimer's disease and frontotemporal dementia: evidence for rostrocaudal asymmetry.
NPJ Aging. 2025 Jun 9;11(1):50. doi: 10.1038/s41514-025-00243-y.
7
FDG-PET Image Classification in Alzheimer's Disease: from Traditional Visual Analysis to Advanced Transfer Learning.
Nucl Med Mol Imaging. 2025 Jun;59(3):201-208. doi: 10.1007/s13139-025-00908-2. Epub 2025 Feb 24.
8
Quantitative magnetic resonance imaging in Alzheimer's disease: a narrative review.
Quant Imaging Med Surg. 2025 Apr 1;15(4):3641-3664. doi: 10.21037/qims-24-1602. Epub 2025 Mar 28.
9
On-Tissue Chemical Derivatization for Mass Spectrometry Imaging of Fatty Acids with Enhanced Detection Sensitivity.
Biomolecules. 2025 Mar 3;15(3):366. doi: 10.3390/biom15030366.
10
Deep learning in nuclear medicine: from imaging to therapy.
Ann Nucl Med. 2025 May;39(5):424-440. doi: 10.1007/s12149-025-02031-w. Epub 2025 Mar 13.
本文引用的文献
1
Biological markers of Alzheimer's disease.
Arq Neuropsiquiatr. 2014 Mar;72(3):227-31. doi: 10.1590/0004-282x20130233.
2
Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications.
Neurodegener Dis Manag. 2014;4(1):73-81. doi: 10.2217/nmt.13.68.
3
Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.
4
Molecular imaging of Alzheimer disease pathology.
AJNR Am J Neuroradiol. 2014 Jun;35(6 Suppl):S12-7. doi: 10.3174/ajnr.A3847. Epub 2014 Feb 6.
5
Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.
Clin Transl Imaging. 2013 Aug;1(4). doi: 10.1007/s40336-013-0026-y.
6
Disease-modifying drugs in Alzheimer's disease.
Drug Des Devel Ther. 2013 Dec 6;7:1471-8. doi: 10.2147/DDDT.S41431.
7
A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review.
Int J Geriatr Psychiatry. 2014 Jun;29(6):551-61. doi: 10.1002/gps.4036. Epub 2013 Oct 9.
8
[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):290-300. doi: 10.1007/s00259-013-2564-y. Epub 2013 Oct 2.
9
PET approaches for diagnosis of dementia.
AJNR Am J Neuroradiol. 2014 Nov-Dec;35(11):2030-8. doi: 10.3174/ajnr.A3695. Epub 2013 Aug 14.
10
Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.
Alzheimers Dement. 2013 Jul;9(4):e106-9. doi: 10.1016/j.jalz.2013.06.001.
Zotero 插件